CORONA Remedies Ltd. (CORONA) — Tipsheet https://tipsheet.markets/company/corona/ Every Tipsheet Editorial note covering CORONA Remedies Ltd. (CORONA), newest first. Grounded in BSE/NSE primary-source filings. en-in Tue, 28 Jul 2026 14:38:33 GMT Corona Remedies fires up EU-GMP hormone plant, adds 20% capacity https://tipsheet.markets/corona-corona-remedies-fires-up-eu-gmp-hormone-plant-adds-20-capacity-117098/ https://tipsheet.markets/corona-corona-remedies-fires-up-eu-gmp-hormone-plant-adds-20-capacity-117098/ Tue, 30 Jun 2026 16:36:33 GMT The new Ahmedabad facility, spanning 1 lakh sq ft, targets regulated export markets with 194M tablets/capsules annual capacity, turning a regulatory milestone into revenue generation. The new Ahmedabad facility, spanning 1 lakh sq ft, targets regulated export markets with 194M tablets/capsules annual capacity, turning a regulatory milestone into revenue generation.

What’s new

  • Commercial production begins at EU-GMP approved Women's Hormone facility in Bhayla, Ahmedabad.
  • Annual capacity: 194M tablets/capsules and 1.5M ointments/gels.
  • In-house hormone capacity rises nearly 20%, boosting export and domestic reach.

Why it matters

The plant converts a previously disclosed EU-GMP certification into a revenue-generating asset. For a mid-cap pharma with trailing revenue growth of 20% and PAT growth of 44%, dedicated hormone capacity for regulated export markets is a material growth lever.

What we’re watching

  • Revenue contribution from the new plant in coming quarters.
  • Securing of export contracts for complex hormone therapies.
  • Margin improvement from higher-value product mix.

The full read

Corona Remedies just switched on its EU-GMP Women's Hormone plant in Ahmedabad. Hardly routine. The 1 lakh sq ft facility adds nearly 20% to in-house hormone capacity, producing 194 million tablets/capsules and 1.5 million ointments/gels annually—enough to target regulated export markets. This converts a previously disclosed regulatory milestone into a tangible revenue contributor. For a mid-cap pharma with trailing revenue growth of 20% and PAT growth of 44%, the dedicated hormone capacity is a material growth lever, even if the exact revenue impact remains unguided.

Primary source: BSE · NSE

]]> Other Tipsheet Editorial